^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

XYF19 CAR-T cells

i
Other names: XYF19 CAR-T cells, CD19-specific CAR-T cells with edited endogenous HPK1
Associations
Trials
Company:
Xi'An Yufan Biotech
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
over2years
DECREASING HPK1 EXPRESSION IN CD19 CAR-T CELLS: A NOVEL STRATEGY TO OVERCOME CHALLENGES OF CELL THERAPY FOR ADULT (R/R) B-ALL (EHA 2022)
The cell dosage of XYF19 was significantly lower than Tecartus and Kymriah, participants were infused with XYF19 CAR-T cells: 3 at low dose (2.0×10 5 /kg), 5 at medium dose (5.0×10 5 /kg), and 3 at high dose (1.0×10 6 /kg). All patients received a conditioning regimen of IV fludarabine (30mg/m 2 /d) for 4 days and cyclophosphamide (500mg/m 2 /d) for 2 days...Conclusion Treatment with XYF19 CAR-T cells promises a novel treatment that can alleviate some of the stern challenges of CD19 CAR-T cell therapy for adult patients with r/r B-ALL. In the current study, this treatment showed robust activity against adult (r/r) B-ALL without >Grade 2 toxicity. This efficacy and safety will be demonstrated in further trials with larger sample sizes.
Clinical • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • XYF19 CAR-T cells